专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明申请

WO1993024624A1 t-PA MODIFICATION 审中-公开
标题翻译： t-PA修改
公开(公告)号：WO1993024624A1
公开(公告)日：1993-12-09
申请号：PCT/JP1992000679
申请日：1992-05-26
申请人： SUMITOMO PHARMACEUTICALS COMPANY, LIMITED , SATO, Hideshi , TAKAHASHI, Sene , NEGORO, Takaharu , SUDO, Yoshiaki , AGUI, Hideo
发明人： SUMITOMO PHARMACEUTICALS COMPANY, LIMITED
IPC分类号： C12N09/64
CPC分类号： C12N9/6459 , A61K38/00 , C12Y304/21069
摘要： A tissue plasminogen activator (t-PA) modification prepared by inserting a spacer comprising an oligopeptide composed of several to tens of amino acid residues into a single-strand cleavage site of t-PA. When it is in the form of a single strand, it is lowly active and resistant to plasminogen activator inhibitor 1. When converted into the form of a double strand at a thrombotic part of a patient, it has an activity substantially equivalent to that of natural t-PA. Accordingly, it is remarkably excellent as a therapeutic thrombolytic agent, because it has an efficacy substantially equivalent to that of natural t-PA even in a smaller dose and has less side effects.
摘要翻译：通过将包含由数十至数十个氨基酸残基组成的寡肽的间隔物插入到t-PA的单链切割位点而制备的组织纤溶酶原激活剂（t-PA）修饰。当其为单链形式时，其具有低活性并且对纤溶酶原激活物抑制剂1具有抗性。当在患者的血栓形成部分转化为双链形式时，其活性基本上等同于天然 T-PA。因此，作为治疗性溶栓剂是非常优异的，因为即使在较小剂量下也具有与天然t-PA相当的功效，副作用较小。

22. 发明申请

WO1993011238A1 HUMANIZED B-B10, AN ANTI-IL2 RECEPTOR ANTIBODY 审中-公开
标题翻译：人类B-B10，抗IL2受体抗体
公开(公告)号：WO1993011238A1
公开(公告)日：1993-06-10
申请号：PCT/JP1992001583
申请日：1992-12-03
申请人： SUMITOMO PHARMACEUTICALS COMPANY, LIMITED , BIOTEST PHARMA GMBH , INNOTHERAPIE LABORTOIRES , NAKATANI, Tomoyuki , GOMI, Hideyuki , WIJDENES, John , NOGUCHI, Hiroshi
发明人： SUMITOMO PHARMACEUTICALS COMPANY, LIMITED , BIOTEST PHARMA GMBH , INNOTHERAPIE LABORTOIRES
IPC分类号： C12N15/13
CPC分类号： C07K16/2866 , A61K38/00 , C07K16/465 , C07K2317/24
摘要： A humanized antibody is provided, which is obtained by transplantation of the complementarity determining region of a mouse monoclonal antibody B-B10 specific to a human IL-2 receptor into a human antibody. The antibody has a very low antigenicity, and therefore, it is useful for treatment of carcinoma expressing IL-2 receptor.
摘要翻译：提供通过将人IL-2受体特异性的小鼠单克隆抗体B-B10的互补决定区移植到人抗体中而获得的人源化抗体。抗体具有非常低的抗原性，因此可用于治疗表达IL-2受体的癌症。

23. 发明申请

WO1998015628A1 NOVEL SEMAPHORIN GENE: SEMAPHORIN W 审中-公开
标题翻译：新葡萄糖基因：SEMAPHORIN W
公开(公告)号：WO1998015628A1
公开(公告)日：1998-04-16
申请号：PCT/JP1997003549
申请日：1997-10-03
申请人： SUMITOMO PHARMACEUTICALS COMPANY, LIMITED , KIMURA, Toru , KIKUCHI, Kaoru
发明人： SUMITOMO PHARMACEUTICALS COMPANY, LIMITED
IPC分类号： C12N15/12
CPC分类号： C07K14/4703 , A01K2217/05 , A61K38/00
摘要： Semaphorin W having an inhibitory effect on nerve extension and its gene; other semaphorins hybridizable with the semaphorin W gene; modified proteins and partial peptides of the semaphorin W; an antibody against the semaphorin W; an antisense nucleotide of the semaphorin W gene; the use of these substances as medicines, diagnostic drugs or research reagents; a method for screening semaphorin W antagonists with the use of the semaphorin W; semaphorin W antagonists obtained by this screening method; medicines containing these antagonists; and transgenic animals, etc. relative to the semaphorin W.
摘要翻译：对神经延伸具有抑制作用的信号素W及其基因; 其他信号素可与信号素W基因杂交; 改变的蛋白质和semaphorin W的部分肽; 针对信号素W的抗体; 信号素W基因的反义核苷酸; 使用这些物质作为药物，诊断药物或研究试剂; 使用信号素W筛选信号素W拮抗剂的方法; 通过该筛选方法获得的信号素W拮抗剂; 含有这些拮抗剂的药物; 和转基因动物等相对于semaphorin W.

24. 发明申请

WO1998009965A1 NOVEL 'beta'-LACTAM COMPOUNDS AND PROCESS FOR PREPARING THE SAME 审中-公开
标题翻译：新型β--LACTAM化合物及其制备方法
公开(公告)号：WO1998009965A1
公开(公告)日：1998-03-12
申请号：PCT/JP1997003078
申请日：1997-09-03
申请人： SUMITOMO PHARMACEUTICALS COMPANY, LIMITED , SUNAGAWA, Makoto , YAMAGA, Hiroshi , NOUDA, Hiroshi , SHINAGAWA, Hisatoshi
发明人： SUMITOMO PHARMACEUTICALS COMPANY, LIMITED
IPC分类号： C07D487/04
CPC分类号： C07D477/20
摘要： beta -Lactam compounds represented by general formula (1) and salts and esters thereof, wherein R represents a lower alkyl or an OH-substituted lower alkyl; R represents H or a lower alkyl; X represents O, S, or NH; n is 1 to 3; and R represents -C(Ra)=NH (wherein Ra represents H, a lower alkyl, or a substituted lower alkyl). The above compounds have an excellent antimicrobial activity against Gram-positive bacteria, particularly meticillin-resistant staphylococci and meticillin-resistant and coagulase-negative staphylococci.
摘要翻译：由通式（1）表示的β-内酰胺化合物及其盐和酯，其中R 1表示低级烷基或OH-取代的低级烷基; R 2表示H或低级烷基; X表示O，S或NH; n为1〜3; 并且R 3表示-C（R a）= NH（其中R a表示H，低级烷基或取代的低级烷基）。上述化合物对革兰氏阳性菌，特别是耐甲氧西林葡萄球菌和耐甲氧西林和凝固酶阴性葡萄球菌具有优异的抗菌活性。

25. 发明申请

WO1998001152A1 REMEDIES FOR EATING DISTURBANCE 审中-公开
标题翻译：补救干扰的补救措施
公开(公告)号：WO1998001152A1
公开(公告)日：1998-01-15
申请号：PCT/JP1997002283
申请日：1997-07-02
申请人： SUMITOMO PHARMACEUTICALS COMPANY, LIMITED , HASHIZUME, Kiyoshi
发明人： SUMITOMO PHARMACEUTICALS COMPANY, LIMITED
IPC分类号： A61K38/27
CPC分类号： A61K38/27
摘要： Remedies for abnormalities in eating attitudes caused by anorexia nervosa. Although it has been a practice to use tranquilizers, etc. for treating mental symptoms characteristic of anorexia nervosa typified by abnormalities in eating attitudes, such as refusal of food, intentional vomiting and eating in secret, only poor effects can be achieved thereby. The administration of the above-mentioned remedies, i.e., human growth hormone (hGH) preparations makes it possible to impart the spontaneous will to eat to those who can get nourishment exclusively by passive means such as compulsory nutritional education or nasal feeding. These remedies are particularly efficacious against eating disturbance of anorexia nervosa seemingly based on the hypersecretion in the central growth hormone releasing factor (GRH)-hGH secretion system.
摘要翻译：对由神经性厌食症引起的饮食态度异常的补救措施。尽管使用镇定剂等来治疗食欲不振症状特征的精神症状特征，如拒绝食物，故意呕吐和秘密进食，但只能效果差。上述治疗方法，即人生长激素（hGH）制剂的施用使得可以将自发的意愿赋予仅能通过被强制营养教育或鼻饲的被动方式获得营养的人。这些补救措施对于神经性厌食症的饮食障碍特别有效，这似乎是基于中枢生长激素释放因子（GRH）-hGH分泌系统中的过度分泌。

26. 发明申请

WO1997021344A1 PATHOLOGIC ANIMAL HAVING PLEURISY 审中-公开
标题翻译：有病的动物动物
公开(公告)号：WO1997021344A1
公开(公告)日：1997-06-19
申请号：PCT/JP1996003649
申请日：1996-12-13
申请人： SUMITOMO PHARMACEUTICALS COMPANY, LIMITED , KOIKE, Haruhiko , PHILLIPS, M., Laurie
发明人： SUMITOMO PHARMACEUTICALS COMPANY, LIMITED
IPC分类号： A01K67/027
CPC分类号： A01K67/027
摘要： The present invention provides a novel pathologic animal having pleurisy and a method for preparation thereof. Said pathologic animal is prepared by administration of lipoteichoic acid, and useful for screening a substance for preventing or treating inflammation such as pleurisy.
摘要翻译：本发明提供一种具有胸膜炎的新型病理动物及其制备方法。所述病理动物通过施用脂磷壁酸制备，并且可用于筛选用于预防或治疗诸如胸膜炎等炎症的物质。

27. 发明申请

WO1997018703A1 METHOD FOR CONSTRUCTING TRANSGENIC ANIMALS 审中-公开
标题翻译：构建转基因动物的方法
公开(公告)号：WO1997018703A1
公开(公告)日：1997-05-29
申请号：PCT/JP1996003375
申请日：1996-11-18
申请人： SUMITOMO PHARMACEUTICALS COMPANY, LIMITED , TOYODA, Yutaka , SAITO, Izumu
发明人： SUMITOMO PHARMACEUTICALS COMPANY, LIMITED
IPC分类号： A01K67/027
CPC分类号： A01K67/0275 , A01K2217/05 , C12N15/86 , C12N2710/10343
摘要： A method for conveniently and efficiently constructing transgenic animals comprising infecting a fertilized animal egg for which the egg membrane has been eliminated with a non productive recombinant Adenovirus having a foreign gene introduced thereinto and then transplanting the embryo into the uterus of a host.
摘要翻译：一种方便，有效地构建转基因动物的方法，包括用引入外源基因的非生产性重组腺病毒感染已经消除了卵膜的受精动物卵，然后将胚胎移植到宿主的子宫中。

28. 发明申请

WO1995009908A1 NOVEL TISSUE PLASMINOGEN ACTIVATOR ANALOG 审中-公开
标题翻译：新组织PLASMINOGEN ACTIVATOR ANALOG
公开(公告)号：WO1995009908A1
公开(公告)日：1995-04-13
申请号：PCT/JP1994001629
申请日：1994-09-30
申请人： SUMITOMO PHARMACEUTICALS COMPANY, LIMITED , NEGORO, Takaharu , SATO, Hideshi
发明人： SUMITOMO PHARMACEUTICALS COMPANY, LIMITED
IPC分类号： C12N09/64
CPC分类号： C12N9/6456 , C07K2319/00
摘要： A novel tissue plasminogen activator (t-PA) analog having such an amino acid sequence that the whole or a part of the amino acid sequence corresponding to the sequence of 280th to 304th amino acid residues in natural t-PA is replaced by the amino acid sequence of the corresponding UK and that the replacement region at least contains the sequence of Tyr-Arg-Arg-His (SEQ ID NO: 1), i.e., the 177th to 180th amino acid residues of UK corresponding to the sequence of 294th to 298th amino acid residues of natural t-PA. The analog has an increased fibrin specificity and is expected to be usable as a thrombosis remedy reduced in the side effect of t-PA, i.e., systemic bleeding tendency.
摘要翻译：具有这样的氨基酸序列的新型组织纤溶酶原激活物（t-PA）类似物，其中天然t-PA中与280〜304位氨基酸残基相对应的氨基酸序列的全部或一部分被氨基酸并且替换区域至少含有Tyr-Arg-Arg-His（SEQ ID NO：1）的序列，即第294至298位序列的英国第177至第180位氨基酸残基天然t-PA的氨基酸残基。类似物具有增加的纤维蛋白特异性，并且预期可用作减少t-PA的副作用即全身性出血倾向的血栓形成药物。

29. 发明申请

WO1994018566A1 METHOD OF ASSAYING SPECIFIC ANTIBODY 审中-公开
标题翻译：测定特异性抗体的方法
公开(公告)号：WO1994018566A1
公开(公告)日：1994-08-18
申请号：PCT/JP1993000143
申请日：1993-02-04
申请人： SUMITOMO PHARMACEUTICALS COMPANY, LIMITED , TANAKA, Satoshi
发明人： SUMITOMO PHARMACEUTICALS COMPANY, LIMITED
IPC分类号： G01N33/543
CPC分类号： G01N33/54306
摘要： A method of assaying a specific antibody comprising the steps of: (A) forming a complex composed of a labeled antigen, a specific antibody and a carrier-borne antigen in a first reaction system comprising a mixture of the labeled antigen, the carrier-borne antigen and a sample solution containing the specific antibody, said labeled antigen being an antigen against a specific antibody to be assayed and being bonded to a labeled substance in advance, and said carrier-borne antigen being an antigen against said specific antibody and being bonded to a carrier in advance, (B) separating the carrier after the reaction from the first reaction system and mixing the separated carrier with the labeled antigen to prepare a second reaction system, and (C) separating the carrier after the reaction from the second reaction system and determining the amount of the labeled substance bonded to the separated carrier. A complete complex composed of the labeled antigen, the specific antibody and the carrier-borne antigen can be formed in the first reaction system for the reaction among both of said antigens and said antibody by mixing both of said antigens and the sample solution containing said antibody. Further, when an incomplete complex composed of the carrier-borne antigen and the specific antibody is present in the second reaction system, said complete complex can be formed by separating the carrier after the reaction from the first reaction system and mixing the separated carrier with the labeled antigen. Accordingly, the determination of the amount of the labeled substance bonded to the carrier separated after the reaction from the second reaction system enables the target specific antibody to be assayed with high sensitivity by solving the problem of prozoning.
摘要翻译：一种测定特异性抗体的方法，包括以下步骤：（A）在第一反应体系中形成由标记抗原，特异性抗体和载体携带抗原组成的复合物，该第一反应系统包含标记的抗原，载体载体抗原和含有特异性抗体的样品溶液，所述标记的抗原是针对待测定的特异性抗体的抗原，并预先与标记物质结合，所述载体携带抗原是针对所述特异性抗体的抗原，并与载体，（B）将反应后的载体与第一反应体系分离，并将分离的载体与标记的抗原混合，制备第二反应体系，（C）将反应后的载体与第二反应体系并确定结合到分离载体的标记物质的量。通过混合所述抗原和含有所述抗体的样品溶液，可以在第一反应体系中形成由标记抗原，特异性抗体和载体携带抗原组成的完整复合物，用于所述抗原和所述抗体两者之间的反应。此外，当在第二反应体系中存在由载体载体抗原和特异性抗体构成的不完全复合物时，可以通过将反应后的载体与第一反应体系分离并将分离的载体与标记抗原。因此，与第二反应体系反应后分离出的与载体结合的标记物质的量的测定，能够通过解决分散问题，高灵敏度地测定目标特异性抗体。

30. 发明申请

WO1994007498A1 PHARMACEUTICAL COMPOSITION FOR INHIBITING TUMOR NECROSIS FACTOR PRODUCTION 审中-公开
标题翻译：用于抑制肿瘤坏死因子产生的药物组合物
公开(公告)号：WO1994007498A1
公开(公告)日：1994-04-14
申请号：PCT/JP1993001443
申请日：1993-10-07
申请人： SUMITOMO PHARMACEUTICALS COMPANY, LIMITED , IRIE, Kenji , UEDA, Yataka , FUJIWARA, Norio
发明人： SUMITOMO PHARMACEUTICALS COMPANY, LIMITED
IPC分类号： A61K31/505
CPC分类号： C07D409/04 , A61K31/505 , C07D239/80 , C07D239/82 , C07D487/04 , Y02A50/411
摘要： A quinazoline compound represented by general formula (1) or (2), which inhibits significantly the production or secretion of tumor necrosis factors and is efficacious as a remedy for diseases in whose crisis the tumor necrosis factors are believed to participate, wherein R1 through R7 and A represent each a specified functional group.
摘要翻译：由通式（1）或（2）表示的喹唑啉化合物，其显着抑制肿瘤坏死因子的产生或分泌，并且作为其危害的疾病的肿瘤坏死因子被认为参与的疾病是有效的，其中R1至R7 而A代表每个指定的功能组。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式